Evaluation of the exposure equivalence of oral versus intravenous temozolomide. - Wikidata - wikimedia - TriplyDB

Evaluation of the exposure equivalence of oral versus intravenous temozolomide.

Evaluation of the exposure equivalence of oral versus intravenous temozolomide.

http://www.wikidata.org/entity/Q33599155

about

Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas Development of a new UPLC-MSMS method for the determination of temozolomide in mice: application to plasma pharmacokinetics and brain distribution study.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.What is the role of chemotherapy in the treatment of melanoma?A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m(2) (Dralitem(®) vs. Temodal(®) Capsules) in Patients with Primary Tumors of the Central Nervous System Under Fasting Conditions.In Vitro Radiosensitizing Effects of Temozolomide on U87MG Cell Lines of Human Glioblastoma Multiforme.In situ electrochemical evaluation of anticancer drug temozolomide and its metabolites-DNA interaction.Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design.Success at last: a molecular factor that informs treatment.Irinotecan and temozolomide brain distribution: a focus on ABCB1.Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.Glioblastoma Treatments: An Account of Recent Industrial Developments

P2860

Q34426355-0C9B0109-4F13-44CF-B1D8-092D34DDFF79 Q34597636-0EFD0355-EB05-4751-AE97-7369838A0293 Q38082728-99697187-89F7-404C-AA82-BEEF3CEE6B61 Q38193716-267A9CFA-1F95-4FBF-9845-3C8B9DF4F922 Q38373115-9AEE9A3D-33B0-40F4-8B84-60EAF44D0454 Q38769884-BC901331-0A39-47FB-BA1B-AB6BDA13CC88 Q43792451-3DC32020-706F-4180-8DCE-CD397B31F018 Q47894210-72E08B5A-2290-4D33-BA1C-34860A9F255B Q48250296-D0CCADC2-0013-47C1-A708-84C661007958 Q48761910-2F2B9FD5-F75A-4619-9BA8-06837DDBF581 Q49093789-E091B48D-D217-4645-ADF6-6698634CBB50 Q57111067-F0EDA711-3B56-4562-9A23-FA030C4BE483

P2860

Evaluation of the exposure equivalence of oral versus intravenous temozolomide.

http://www.wikidata.org/entity/Q33599155

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Evaluation of the exposure equivalence of oral versus intravenous temozolomide.

@ast

Evaluation of the exposure equivalence of oral versus intravenous temozolomide.

@en

type

label

Evaluation of the exposure equivalence of oral versus intravenous temozolomide.

@ast

Evaluation of the exposure equivalence of oral versus intravenous temozolomide.

@en

prefLabel

Evaluation of the exposure equivalence of oral versus intravenous temozolomide.

@ast

Evaluation of the exposure equivalence of oral versus intravenous temozolomide.

@en

P1433

Q33599155-948B619C-A005-4C79-8EC5-27A5F5325C4A

P1476

Q33599155-A31647A0-7C44-4A31-954F-306FC08DAAD3

P2093

Q33599155-0A59ABA4-F33D-4369-96BB-913E03802BDC

Q33599155-2E4C5A56-55FF-4DFC-89D0-6C325825D1A4

Q33599155-35B17CC3-BFE2-438D-9BC9-6D2168633BC4

Q33599155-899DF529-9818-4FE4-B447-C875455A1329

Q33599155-9FCDC589-FB0E-47D3-8FC5-FBFB2CFCFB0B

Q33599155-A8E5E170-BE05-45D7-A278-54AADB9404F8

Q33599155-AF3513AA-E083-46AA-9D06-891F4DD0ED9B

Q33599155-B0D9C247-D718-4CAB-AA93-AECBE9499F77

Q33599155-BB2A1752-EEC1-4AF4-A821-BBA45FF2465C

Q33599155-DF046B2F-040A-4AB8-B5A7-931E9CBBE278

P2860

Q33599155-0F5995AF-8947-4AB0-91BA-3E18C3DFDE8E

Q33599155-274EEEB0-2868-4BC4-88CB-92E3E8EE553B

Q33599155-27FA3025-F188-452C-8BBF-5BAA1C628E45

Q33599155-448193DB-19A2-4463-8A4F-A0E08908AA8E

Q33599155-5E391B6D-2028-4F9C-9D75-5F0A9D432821

Q33599155-6309F472-C263-4B01-B445-588E7D6FCA8C

Q33599155-6DD48FEB-DB16-4753-9CC5-E2FCB061D6AD

Q33599155-794AD88F-99CC-4A8B-827E-E2B0B306F19E

Q33599155-834E2A6E-73B7-423A-AECC-D0C2C9E0BCFF

Q33599155-88A9AC06-7C88-4925-9F5B-1D0D9C915989

P2888

Q33599155-A5A8F9B7-38D3-4916-BFE4-4218E5E801FA

P304

Q33599155-BDE7B5EA-8763-4074-B71C-39D32689C409

P31

Q33599155-349A71EF-E415-48ED-A582-A8249766193C

P356

Q33599155-2E903A74-A898-42DF-A3F6-B4C399BFB91C

P433

Q33599155-8AE10085-E9F1-4953-B9D1-2B9DCD0CF5DC

P478

Q33599155-2FE621E8-2224-4CAB-A19E-FBC8ED0D453B

P577

Q33599155-E738E3D6-03DA-4247-A922-C4BA9FD2CF15

P5875

Q33599155-40FE53BB-0D0C-4B0E-B298-0E6327E3B9FD

P6179

Q33599155-BFE70DF2-7C77-48FD-834A-5A540525C16D

P698

Q33599155-81C1E637-EC18-468F-83BF-B0770E1E4330

P932

Q33599155-80460EFE-D041-4BCE-B303-C0DA806C3D48

P356

S00280-009-1078-6

P1433

Cancer Chemotherapy and Pharmacology

P1476

Evaluation of the exposure equivalence of oral versus intravenous temozolomide.

@en

P2093

Bhavna Kantesaria

http://www.w3.org/2001/XMLSchema#string

Blanca D Diez

http://www.w3.org/2001/XMLSchema#string

David Cutler

http://www.w3.org/2001/XMLSchema#string

Fabio H Ottaviano

http://www.w3.org/2001/XMLSchema#string

Fengjuan Xuan

http://www.w3.org/2001/XMLSchema#string

Malaz A Abutarif

http://www.w3.org/2001/XMLSchema#string

Marc Cantillon

http://www.w3.org/2001/XMLSchema#string

Maria Guadalupe Pallotta

http://www.w3.org/2001/XMLSchema#string

Max Schwarz

http://www.w3.org/2001/XMLSchema#string

Paul Statkevich

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I trial of temozolomide (CCRG 81045: M&B; 39831: NSC 362856)

Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

Population pharmacokinetics of temozolomide in cancer patients.

Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.

Phase I trial of temozolomide using an extended continuous oral schedule.

Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.

Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates.

P2888

s00280-009-1078-6

P304

727-734

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-009-1078-6

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26704625

http://www.w3.org/2001/XMLSchema#string

P6179

1029347289

http://www.w3.org/2001/XMLSchema#string

P698

19641919

http://www.w3.org/2001/XMLSchema#string

P932

2808524

http://www.w3.org/2001/XMLSchema#string